Overview
Treating and preventing maternal and child wasting depends on reliable access to specialised nutrition products. In Pakistan, these products are mostly supported through short-term humanitarian funding and are not part of long-term development planning. CERP studied the market for 4 lipid-based nutrition supplements: RUTF, RUSF, LNS-MQ, and LNS-PLW, along with their local equivalents. The study ran from November 2022 to November 2024 and focused on Khyber Pakhtunkhwa, examining regulation, finance, demand and supply to find what blocks wider use of these products.
CERP also serves as an implementation and technical partner on nutrition initiatives, including work with R4D under the Finance Capacity Development Platform (FCDP), where it acts as an Asia partner on nutrition financing to strengthen nutrition financing.
Tools and Methods Used
CERP reviewed national survey data, policy documents and existing research to develop hypotheses. The team conducted a multi-stakeholder analysis by holding in-depth interviews with federal and provincial government partners, UNICEF, WFP and donors. CERP mapped manufacturers, suppliers and sales channels, including a thorough market visit in Peshawar. All findings were organised into a landscape analysis covering regulation, finance, demand and supply.
Impact Achieved
The study showed that treatment coverage stays below 10% a year and depends heavily on donor funding. It found that key products are missing from Pakistan’s Essential Medicines List, which makes procurement harder. CERP found out that only one local manufacturer remained in the area. To address this gap government and private organisations were invited to a series of workshops to share their vision, roadblocks and way forward for nutrition interventions in Pakistan. As a result, provincial level action plans were developed and CERP recommended strengthening the regulatory role of DRAP (the Drug Regulatory Authority of Pakistan), bringing procurement into routine health systems, and researching cheaper local alternatives.